Navigation Links
Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent
Date:5/7/2008

rrence of unanticipated events.

VOLCANO CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

(Unaudited)

March 31, December 31,

2008 2007

Assets

Current assets:

Cash and cash equivalents $132,572 $122,913

Short-term available-for-sale

investments 55,539 66,205

Accounts receivable, net 25,293 27,976

Inventories 22,399 21,243

Prepaid expenses and other current

assets 3,979 3,997

Total current assets 239,782 242,334

Restricted cash 376 365

Property and equipment, net 14,814 13,692

Intangible assets, net 8,641 9,385

Other non-current assets 804 798

$264,417 $266,574

Liabilities and Stockholders' Equity

Current liabilities:

Accounts payable $10,051 $11,077

Accrued compensation 8,250 9,083

Accrued expenses and other current

liabilities 6,326 6,600

Deferred revenues 5,796 5,360

Current maturities of long-term debt 58 120

Total current liabilities 30,481 32,240

Long-term debt
'/>"/>

SOURCE Volcano Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Volcano Corporation Presentation at Bear Stearns Conference to be Webcast
2. Volcano Corporation Announces Pricing of Common Stock Offering
3. Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated
4. Volcano Announces Closing of CardioSpectra Acquisition
5. Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast
6. Volcano Announces FDA 510(k) Clearance of Revolution Rotational Catheter and FFR for the s5i Integrated IVUS Console
7. Volcano Corporation Presentation at Cowen Healthcare Conference to be Webcast
8. Volcano Announces U.S. and European Launch of Rotational IVUS and Integrated FFR
9. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
10. QMed, Inc. Reports July Medicare SNP Enrollments
11. Phlo Affiliate Reports Expanded Coverage to Oregon Border
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... , May 21, 2015  Prima Biomed Ltd. ... that is striving to become a leader in the ... recently announced that the final CVac data from the ... a clear trend for a clinically meaningful improvement in ... second remission patients. In the group of ...
(Date:5/21/2015)...  The EveryLife Foundation for Rare Diseases applauded ... Amy Klobuchar (D-MN) today for introducing the ... or OPEN ACT. Supported by more ... bipartisan legislation promises to rapidly bring hundreds of ... patients by incentivizing drug makers to "repurpose" approved ...
(Date:5/21/2015)... 2015 W. R. Grace & ... in Worms, Germany has received good manufacturing practice ... the International Pharmaceutical Excipient Council (IPEC) Foundation. ... its SYLOID® FP brand of pharmaceutical grade excipient ... the Curtis Bay, Maryland (USA) and Sorocaba, Brazil ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
Breaking Biology Technology:Correction Continues after Big Move - BrokerBank Securities, Inc. 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7
... March 28, 2011 DRIVE4COPD, the nation,s single largest ... named PRWeek,s Healthcare Campaign of the Year ... the most prestigious honors in the public relations industry, ... and education teams.  Boehringer Ingelheim Pharmaceuticals, Inc. is the ...
... March 28, 2011 Clinicians now have a new tool ... and HSV2) -- one of the most common sexually transmitted ... segment of BD (Becton, Dickinson and Company), announced today that ... for the first fully automated molecular tests to detect and ...
... March 28, 2011 BioMarin Pharmaceutical Inc. ... that Jean-Jacques Bienaime, Chief Executive Officer of ... webcast on Thursday, April 28, at 5:00 ... financial results.U.S. / Canada Dial-in Number:  888.396.2386International ...
Cached Biology Technology:DRIVE4COPD Wins PRWeek Healthcare Campaign of the Year 2011 2DRIVE4COPD Wins PRWeek Healthcare Campaign of the Year 2011 3DRIVE4COPD Wins PRWeek Healthcare Campaign of the Year 2011 4BD Diagnostics Receives FDA Clearance for First Fully Automated Molecular Assays for HSV1 and HSV2 from Clinician-Collected External Anogenital Lesion Specimens 2BioMarin to Host First Quarter 2011 Financial Results Conference Call and Webcast on Thursday, April 28 at 5:00 p.m. ET 2
(Date:4/17/2015)... 2015 Increasing adoption ... advancement to drive biometric systems market in ... According to a recently released TechSci ... ", biometric systems market in Saudi ... at CAGR of over 22% through 2020. The ...
(Date:4/13/2015)... 13, 2015 According to ... Biometrics Market Forecast & Opportunities, 2020", the global biometrics ... around 14% till 2020. The biometrics market is ... implementation and review of biometric management systems. The ... products with greater efficiency, are resulting in increasing ...
(Date:4/9/2015)... April 9, 2015 Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 2015, after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2Synaptics to Report Third Quarter Results on April 23 2
... November 9, 2010 The Ontario Genomics Institute (OGI) ... at St. Joan of Arc Catholic Secondary School (Mississauga, ... Prize. The annual prize recognizes the Ontario secondary ... preparing Ontario,s students for their future roles: perhaps ...
... University of Toronto have shown that the nature of ... individual,s sensitivity to physical pain. The discovery could ... general well-being of an individual on a daily basis. ... have demonstrated the impact of inadequate social connectedness on ...
... activity of nerve cells in a songbird,s brain as it ... in the Department of Physics at Penn State University and ... string together sets of syllables -- or notes in a ... brain learns language and produces speech. The research will be ...
Cached Biology News:Mississauga teacher awarded prize for excellence in teaching genomics 2Mississauga teacher awarded prize for excellence in teaching genomics 3Psychologists identify influence of social interaction on sensitivity to physical pain 2Scientists discover how the songbird's brain controls timing during singing 2
... a special preparation of bovine pancreatic DNase I ... of DNA molecules. In the presence of Mn2+ ... strand breaks at random sites in DNA. The ... controlled by the enzyme concentration and incubation time. ...
... potent TURBO DNase (patent pending) in the TURBO ... DNA removal capabilities. TURBO DNase is a recombinant, ... more efficient than wild type DNase I in ... DNase binds DNA substrates 6-fold more tightly than ...
... IEC Centra CL3 series is designed ... research and clinical applications at a ... package includes quick connect rotors and ... yet intuitive interface allows you to ...
Porcine Pulmonary Artery Endothelial Cells (PPAEC) (>500,000 cells)...
Biology Products: